Clinical Trial Update: Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial assessing long-term efficacy and safety of two doses of NN-220 (somatropin) in short stature due to Noonan syndrome has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genetic Disorder
• Noonan Syndrome

Drugs mentioned

• NN-220 (somatropin)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Genetic Disorder, Noonan Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2019-10-14